David Sides: We haven’t heard anything in the last couple of weeks. We still have time to sign up more providers. So we’re optimistic that this won’t be the final number that we end up at. But we haven’t heard it come through the marketplace yet from those changes.
Jailendra Singh: Okay. And one last one. On the free cash flow trend, I think you talked about that. So just any guidance you can provide for the year, like any number just to make sure we are in the ballpark?
James Arnold: No. We tried to share that for next quarter we’re expecting it to be negative because of the cash payment. Almost $33 million went out with — on the cash payment related to the DOJ issue. And so, obviously, that will be negative. I believe afterwards we will expect cash conversions in the back half of the year and I think of it is probably 50% of EBITDA as we are able to give you a pretty good target area.
David Sides: But for the year, still generating free cash flow on the entire year. Limited free cash flow for the entire year.
Jailendra Singh: All right, guys. Thanks a lot.
Operator: Thank you. [Operator Instructions] Our next question comes from Jessica Tassan with Piper Sandler.
Jessica Tassan: Hi. Thank you guys for taking the question. So I have a few more bookings related ones. Hopefully, you can bear with me. So are the majority of the 72% of bookings from existing customers coming from customers who are upgrading to spring 2021? And if so, just is the completion of that upgrade cycle going to moderate the volume of existing customer bookings? Or are you seeing kind of same-store sales in the month and years subsequent to the upgrades?
David Sides: So the — I mean, the 72% are from the base and now the majority of the base is on the Cures addition. So, I guess, it stands the reason that that’s where — but it’s not because of the Cures Act addition kind of absence or presence, that’s driving the bookings probably. It’s just do they need these things? From an implementation perspective, certainly getting easier that almost everyone is on the Cures addition. So when implementation goes to check, it’s whatever it is, you can put it on this where, I think, probably two years ago without that. There are some newer Surround solutions that require that. That’s pretty much all there now. So there’s no — there’s less work to do to implement at this point because people are all on — most clients are on the same release at this point.
Jessica Tassan: Got it. So just the bookings from existing customers, those are kind of coming through irrespective of the status of the upgrade and should continue to?
David Sides: Yes. I think so.
Jessica Tassan: Got it. And then just any ambulatory market kind of broadly. Do you have any sense of what practices are now 2015 Cures update compliant and what does that mean for just net new bookings prospect? Basically, does a recent update or compliance with the 2015 Cures update mean that a competitive client would be harder to convert or is that kind of a neutral factor or irrelevant to competitive conversion?
David Sides: I think it’s for somebody if they’re not on it, I think it’s a positive for us in that — if you’re not on it, we could get you live by the deadline still. So we’d be happy to take any of those clients through the conversion process to get them live in time. So that is still good for us. And I think that’s mainly a problem on the lower ends. Most of our larger practice competitors are certified by now. Those they’re not upgraded, we’d still offer them an opportunity to come to NextGen. So — but if they’re already on in addition, we could still get them to come to NextGen or not. But the ones that aren’t, I think there’s still probably some movement to happen there in the market.
